User login
Article Type
Changed
Fri, 01/04/2019 - 11:12
Display Headline
Cannabinoids in cancer treatment settings
The legalization of cannabis is one element of an evolving and multidimensional discourse in the United States. That discourse includes disputes about federal law versus state and individual rights; public misunderstandings about the basic tenets of clinical science, such as concepts of causality and how we weigh evidence about treatment effectiveness; and, in an increasingly consumer-driven health care climate, even the role of physicians in recommending treatments for symptoms and diseases. Whether we like it or not, we who work in cancer find ourselves engaged in the practical consequences of these debates. What is a drug? What does it mean for health care professionals to try to discuss the science of the treatment efficacy of substances, such as most “medical marijuana,” that have not been approved by the US Food and Drug Administration (FDA)? How do we find ourselves here?
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 14(1)
Topics
Page Number
1-5
Legacy Keywords
cannabis, medical marijuana, palliative treatment, tetrahydrocannabinol, THC, cannabidiol, CBD, chemotherapy-induced nausea and vomiting, CINV, loss of appetite
Sections
Article PDF
Article PDF
The legalization of cannabis is one element of an evolving and multidimensional discourse in the United States. That discourse includes disputes about federal law versus state and individual rights; public misunderstandings about the basic tenets of clinical science, such as concepts of causality and how we weigh evidence about treatment effectiveness; and, in an increasingly consumer-driven health care climate, even the role of physicians in recommending treatments for symptoms and diseases. Whether we like it or not, we who work in cancer find ourselves engaged in the practical consequences of these debates. What is a drug? What does it mean for health care professionals to try to discuss the science of the treatment efficacy of substances, such as most “medical marijuana,” that have not been approved by the US Food and Drug Administration (FDA)? How do we find ourselves here?
Click on the PDF icon at the top of this introduction to read the full article.
The legalization of cannabis is one element of an evolving and multidimensional discourse in the United States. That discourse includes disputes about federal law versus state and individual rights; public misunderstandings about the basic tenets of clinical science, such as concepts of causality and how we weigh evidence about treatment effectiveness; and, in an increasingly consumer-driven health care climate, even the role of physicians in recommending treatments for symptoms and diseases. Whether we like it or not, we who work in cancer find ourselves engaged in the practical consequences of these debates. What is a drug? What does it mean for health care professionals to try to discuss the science of the treatment efficacy of substances, such as most “medical marijuana,” that have not been approved by the US Food and Drug Administration (FDA)? How do we find ourselves here?
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 14(1)
Issue
The Journal of Community and Supportive Oncology - 14(1)
Page Number
1-5
Page Number
1-5
Topics
Article Type
Display Headline
Cannabinoids in cancer treatment settings
Display Headline
Cannabinoids in cancer treatment settings
Legacy Keywords
cannabis, medical marijuana, palliative treatment, tetrahydrocannabinol, THC, cannabidiol, CBD, chemotherapy-induced nausea and vomiting, CINV, loss of appetite
Legacy Keywords
cannabis, medical marijuana, palliative treatment, tetrahydrocannabinol, THC, cannabidiol, CBD, chemotherapy-induced nausea and vomiting, CINV, loss of appetite
Sections
Citation Override
JCSO 2016;14:1-5
Disallow All Ads
Alternative CME
Article PDF Media
Document